US2023233521A1PendingUtilityA1

Escalating dosing regimen for effecting weight loss and treating obesity

86
Assignee: VIVUS LLCPriority: Jun 9, 2008Filed: Mar 22, 2023Published: Jul 27, 2023
Est. expiryJun 9, 2028(~1.9 yrs left)· nominal 20-yr term from priority
Inventors:Thomas NajarianPeter Y. TamLeland F. Wilson
A61K 31/35A61K 9/4866A61K 31/137A61K 31/7048A61K 31/357A61K 9/20A61K 9/1676A61K 9/5042A61K 9/5073A61K 9/5084A61K 9/167A61K 9/5026A61K 9/5047A61K 31/00A61K 31/135A61P 1/08A61P 11/00A61P 11/06A61P 15/00A61P 19/02A61P 19/06A61P 21/00A61P 25/00A61P 25/02A61P 25/06A61P 25/20A61P 3/04A61P 31/04A61P 35/00A61P 3/06A61P 43/00A61P 9/10A61P 9/12A61P 3/10A61K 9/1629A61K 47/38A61K 9/1623
86
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.

Claims

exact text as granted — not AI-modified
1 . A controlled release composition for treating obesity, diabetes, sleep apnea, or a related condition in a subject comprising:
 an effective amount of topiramate and phentermine.   
     
     
         2 . A method for effecting weight loss in a subject, comprising administering to the subject continually over a significant period of time a daily dose of phentermine in combination therewith a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone.

Join the waitlist — get patent alerts

Track US2023233521A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.